Selank's brain effects differ by administration route: injection targets GABA, nasal spray hits NMDA receptors
Background
The heptapeptide Selank is known for its anxiolytic and nootropic (cognitive-enhancing) properties. However, the route of administration—how a compound enters the body—can significantly alter its pharmacokinetics, biotransformation, and ultimate effects on brain chemistry. Understanding these differences is crucial for optimizing therapeutic protocols. This study investigates whether the delivery method of Selank, either through injection (intraperitoneal) or nasal spray (intranasal), changes its impact on key neurotransmitter systems like the GABAergic and glutamatergic (NMDA) pathways, which are central to regulating anxiety and learning. The research uses two different mouse strains, BALB/c (high anxiety) and C57BL/6 (low anxiety), to see if baseline anxiety levels influence the peptide's effectiveness.
Study Design
Researchers compared two routes of administration for the peptide Selank at 300 μg/kg/day for 5 days: intraperitoneal (i.p.) injection and intranasal (i.n.) spray. The study used two inbred mouse strains: anxious BALB/c mice and less anxious C57BL/6 mice. Behavioral effects were assessed using the elevated-plus-maze test to measure anxiety and exploratory activity. Following the treatment period, brain tissue was analyzed to measure receptor binding density for GABA receptors (using [G-(3)H]SR 95531) in the frontal cortex and NMDA receptors (using [G-(3)H]MK-801) in the hippocampus.
Results
Selank's anxiolytic and nootropic effects were observed only in the high-anxiety BALB/c mice, not in the C57BL/6 strain. The route of administration dramatically changed the underlying neural mechanism in these responsive mice. Intraperitoneal (i.p.) injection of Selank increased the number of GABA receptor binding sites in the frontal cortex by 38%, with no change to NMDA receptors. In contrast, intranasal (i.n.) administration had no effect on GABA receptors but produced a significant increase in NMDA receptor density in the hippocampus.
Intranasal (i.n.) Selank led to an increase in the density of
[G-(3)H]MK-801binding sites by 23%.
This demonstrates that the two delivery methods activate distinct neurochemical pathways to achieve a similar behavioral outcome. I.p. administration appears to work primarily through the GABA system, while i.n. administration works through the NMDA system.
Key Findings
- Intraperitoneal Selank increased GABA receptor binding sites in the frontal cortex by 38% in BALB/c mice.
- Intranasal Selank increased NMDA receptor binding sites in the hippocampus by 23% in BALB/c mice.
- Anxiolytic and nootropic effects of Selank were observed only in the high-anxiety BALB/c mouse strain, not C57BL/6.
- Intraperitoneal Selank did not affect NMDA receptor binding.
- Intranasal Selank had no effect on GABA receptor binding.
Why It Matters
The findings reveal that how you take Selank fundamentally changes how it works in the brain. For users, this implies that an injection protocol and a nasal spray protocol are not interchangeable and may target different aspects of anxiety or cognition. The choice of administration route should be tailored to the desired neurochemical target: GABAergic modulation via injection or glutamatergic (NMDA) modulation via nasal spray. This is a critical consideration for anyone developing a Selank regimen, as the downstream effects could be significantly different. It also highlights the complexity of peptide delivery, suggesting that future research must meticulously document and compare administration routes, as they can lead to entirely different pharmacological profiles for the same compound.
TitrateLab articles covering Selank
Written by TitrateLab, separately from the study summarized above.
